ArticleOncoimmunology
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Shamaila Munir Ahmad et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
trialcites it